obstruction model, the authors showed that mechanical distention induced BNDF expression in the gut smooth muscle cells. BDNF acted on colon-projecting neurons in the dorsal root ganglia (DRG) to suppress the transient A-type K + channel activity, which in turn increased membrane excitability of primary afferent neurons and resulted in visceral hypersensitivity. 7 This mini-review put the findings by Fu's group in a broader perspective by providing an overview of recent discoveries on the roles of neurotrophic factors in enteric physiology and pathophysiology beyond the developmental stage.
| NEUROTROPHI C FAC TOR S AND VISCER AL S ENS ITIVIT Y
Visceral hypersensitivity is present in many gastrointestinal disorders, such as functional dyspepsia, irritable bowel syndrome (IBS), and inflammatory bowel disease. There is an increasing body of evidence suggesting that neurotrophins, particularly NGF and BDNF, are involved in abdominal pain. NGF, by interacting with the primary afferent nerves, contributes to the development of visceral hypersensitivity in several animal models, such as trinitrobenzene sulfonic acid (TNBS), 8, 9 butyrate, 10,11 neonatal maternal deprivation, 12 chronic stress, 13 and bowel obstruction. 14 Several cell types in the digestive tract are known to produce and release NGF, such as intestinal epithelial cells, mast cells, enteric neurons, enteric glial cells, and smooth muscle cells (Table 1) . 10, 12, 15, 16 NGF level is elevated in the colonic mucosa of patients with IBS, 17, 18 and increased expression of NGF is correlated with visceral hypersensitivity in these patients. 18 The mechanisms of NGF action on visceral sensation are not completely understood. Enhancing the activity of pronociceptive receptors and/or ion channels on primary afferent neurons can result in sensory hypersensitivity. NGF increases the transient receptor potential cation channel subfamily V1 (TRPV1) expression in DRG.
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TRPV1 is a nonselective cation channel that mediates scalding heat and pain. Upregulation of TRPV1 by NGF via the phosphoinositide 3-kinase (PI3K)/Akt pathway may contribute to visceral hypersensitivity following TNBS-induced colitis. 19 Mechanical stretch in bowel obstruction causes upregulation of NGF in gut smooth muscle cells. 14 High levels of NGF increase tetrodotoxin-resistant Na + currents in colon-projecting DRG neurons and augment neuronal excitability, which may contribute to visceral hypersensitivity in bowel obstruction. 14 NGF-dependent upregulation of acid-sensing ion channels in colon-projecting DRG neurons is suggested to be involved in butyrate-induced colonic hypersensitivity. 11 Delafoy et al were the first group of researchers to report the involvement of BDNF in visceral hypersensitivity. 8 Intraperitoneal injection (ip) of BDNF decreased sensory threshold to colonic distension in healthy rats. Anti-BDNF antibody (ip) blocked TNBS-induced visceral hypersensitivity. 8 The role of BDNF in visceral hypersensitivity is further supported by the observation that TNBS-induced colonic hypersensitivity was significantly reduced in BDNF heterozygote knock-out (BDNF +/-) mice than that in BDNF +/+ mice. 20 BDNF was mainly present in TRPV1-expressing nociceptive DRG neurons and released into the dorsal horn of the spinal cord to modulate neurotransmission. 21 The expression of BDNF in sensory neurons was kept low in adults at physiological state, but greatly increased after colonic inflammation. 21 BDNF acted on the TrkB receptors on DRG neurons to activate the PLC-γ, but not the MAPK/ERK or PI3K/ Ark pathway, to increase calcitonin-gene related peptide (CGRP) expression during colitis. 22 CGRP is a well-recognized pain mediator.
Increased CGRP expression in the DRG by BDNF may contribute to the activation of visceral nociceptive pathways in colitis.
Besides gut inflammation, early life adverse events may also upregulate BDNF expression in the visceral sensory pathways and contribute to hypersensitivity in adulthood. Winston et al reported that chronic prenatal stress induced visceral hypersensitivity in adult male and female offspring in rats. 23 Chronic prenatal stress also exacerbated visceral hypersensitivity following another episode of chronic stress experienced in adulthood, and the female rats demonstrated a greater and prolonged visceral hypersensitivity than the male rats. Chronic stress in adulthood upregulated BDNF expression in the dorsal horn of the spinal cord of female rats through an epigenetic mechanism of histone acetylation. The increase in BDNF expression was greater in prenatally stressed female rats, which might contribute to the sex specificity of visceral hypersensitivity. 23 Early life colon immune challenge followed by adult colon immune challenge induced similar epigenetic upregulation of BDNF in the DRG and spinal cord and might contribute to the exacerbation of visceral hypersensitivity. 24 The article by Fu et Key Points
• Neurotrophic factors and their receptors are expressed in both fetal and mature gastrointestinal tract.
• Neurotrophic factors play essential roles for the development and migration of the enteric nervous system along the gut during the early stage of life.
• In adult gut, neurotrophic factors are involved in regulation of visceral sensation, motility, epithelial barrier function, and have neuroprotective and neuroplastic effects in the enteric nervous system. These newly recognized functions may have therapeutic implications in bowel disorders and diseases. Human Colon Immune cells in the lamina propria NGF expression is elevated in the colonic mucosa from IBS patients, which may contribute to visceral hypersensitivity and impaired gut barrier function in these patients 17, 18 NT−3 BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; GFR, GDNF family receptor; IBS-D, diarrhea predominant irritable bowel syndrome; N/A, not available; NGF, nerve growth factor; Trk, tropomyosin receptor kinase receptor; NT-3, neurotrophin-3.
| NEUROTROPHI C FAC TOR S AND G UT MOTILIT Y
Effects of neurotrophic factors on gut motility were first recognized as an adverse effect in a clinical trial testing if BDNF would increase survival of amyotrophic lateral sclerosis (ALS) patients. 27 Although the study failed to show benefit of BDNF treatment for ALS, an increased stool frequency occurred in patients treated with a higher dose of BDNF. 27 In addition, exogenous BDNF accelerated gastrointestinal and colonic transit in healthy human volunteers and in patients with constipation. 28 In fasting rats, exogenous BDNF increased myoelectric activity in the gastrointestinal tract. 29 BDNF enhanced peristalsis in the rat colon, 30 and BDNF +/-mice had delayed gastrointestinal transit, slow velocity of fecal pellet propulsion, and decreased stool frequency. 30, 31 BDNF levels were significantly reduced in colonic biopsies from patients with slow transit constipation. 31 All the evidence mentioned above indicates that BDNF has prokinetic effects on gut motility.
The mechanisms underlying the stimulatory effect of BDNF on gut motility are not fully understood and conflicting results have been reported. Gut motility is regulated by the ENS, but BDNF does not directly activate enteric neurons. Instead, it causes a
TrkB-mediated enhancement of Ca 2+ transients induced by serotonin and substance P (SP), suggesting its modulatory role in ENS neural circuits. 32 The neural blocker tetrodotoxin failed to block BDNF-induced enhancement of cholinergic contraction in isolated longitudinal muscle-myenteric plexus strips from the rabbit jejunum. 33 However, tetrodotoxin attenuated BDNF-induced augmentation of contraction in the longitudinal muscle-myenteric plexus strips from the mouse colon. 31 Interestingly, exogenous BDNF had no effect on the basal tone or spontaneous phasic contraction in isolated smooth muscle strips from the rabbit jejunum and mouse ileum and colon, 31, 33 but increased spontaneous phasic contraction in the isolated longitudinal muscle-myenteric plexus strips from the mouse colon. 31 Thus, it is unclear whether BDNF can initiate smooth muscle contraction by itself or it merely augments contraction elicited by other excitatory neurotransmitters. Nevertheless, evidence suggests that BDNF enhanced SP and CGRP-induced smooth muscle contraction in mouse ileum and distal colon, 34 and cholinergic contraction in rabbit jejunum. 33 BDNF-induced enhancement of cholinergic contraction in the rabbit jejunum was mediated through activation of TrkB on smooth muscle cells and subsequent phosphorylation of PLC.
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NGF is also involved in regulation of gut motility. Exogenous NGF increased the gastrointestinal myoelectric activity in fasting rats. 29 NGF overexpression occurred in the rat small intestine after Trichinella spiralis infection. 35 Treatment with anti-NGF antibody in vivo improved the altered gut motility caused by T. spiralis infection, suggesting that NGF plays a role in the development of abnormal gut motility. 35 The role of NT-3 in gut motility was only investigated by exogenous administration. Exogenous NT-3 accelerated gastrointestinal transit in healthy human volunteers. 28 NT-3 also accelerated colonic transit, increased stool frequency, and facilitated passage of stool in constipated patients. 28 In fasting rats, exogenous application of NT-3 increased myoelectric activity in the gastric antrum, duodenum, jejunum, and colon. 29 The role of endogenous NT-3 in adult gut motility remains to be investigated.
| NEUROTROPHI C FAC TOR S AND INTE S TINAL BARRIER
The and impaired intestinal barrier function. 37 Thus, the role of BDNF in regulating intestinal barrier function needs to be further elucidated.
Glial cell-derived neurotrophic factor is recently recognized to play a protective role in intestinal barrier function. Both enteric glial cells and enterocytes can secrete GDNF under physiological condition. 5, 38 GDNF overexpression in transgenic mice reduced dextran sulfate sodium-induced colonic inflammation and loss of intestinal barrier functions. 39 The restoration of intestinal epithelial barrier function by GDNF can be attributed to its anti-apoptotic effects and upregulation of ZO-1 expression in colonic epithelial cells. 39 GDNF also plays a protective role in intestinal barrier integrity against intestinal ischemia-reperfusion injury by upregulating the expression of occludin and ZO-1. 38 In an in vitro study using cultured intestinal epithelial cells, Meir et al found that GDNF exerted no additional barrier-stabilizing effects in the mature barrier formed in differentiated enterocytes, but augmented maturation of epithelial barrier functions in immature intestinal epithelial cells through the cAMP/ protein kinase A and p38 MAPK signaling pathways. 5 Therefore, when considering these findings together with the in vivo observations, it is possible that GDNF might act on the immature epithelial cells in the intestinal crypts.
| ROLE OF NEUROTROPHI C FAC TOR S IN NEUROPROTEC TI ON AND NEUROPL A S TICIT Y IN THE EN S
Recent literature suggests that neurotrophic factors promote the survival and maintenance of neurons and glial cells not only in the developing but also in the adult ENS. One of the earliest articles to report the protective role of GDNF on enteric neuropathy was a study by Anitha et al. 40 Using both in vitro culture system of enteric and p-Akt levels in the colon, which partially rescued the lost enteric neurons in diabetic rats. 43 Similarly, gastric electrical stimulation prevented vagotomy-induced apoptosis of enteric neurons in the stomach, which was mediated by enhanced release of GDNF and activation of its downstream pathway PI3K/Akt. 44 GDNF was also found to protect enteric glial cells from apoptosis induced by gut inflammation through an autocrine mechanism in enteric glial cells. 45 Although BDNF has been known to have neuroprotective effects in the central nervous system, the evidence for neuroprotection in the ENS is scarce. BDNF was shown to inhibit inflammation-induced apoptosis in enteric glial cells. 46 A recent study suggested that BDNF might be able to protect enteric neurons from accumulating mis- patients was associated with a higher nerve fiber density in the lamina propria. 17 Mucosal tissue supernatants from IBS patients stimulated neuritogenesis in an NGF-dependent manner. 17 However, functional consequences of these neuroplastic changes induced by NGF remain unknown.
| CON CLUS I ON S AND FUTURE PER S PEC TIVE S
The role of neurotrophic factors in development and maturation of the nervous system has been exclusively investigated and well physiology is greater than currently apparent. In this respect, it is mandatory to thoroughly investigate the role of neurotrophic factors in enteric physiology and pathophysiology before therapeutic approaches can be administered.
ACK N OWLED G M ENT
The author would like to acknowledge research grant from the National Institutes of Health R15DK097460-01 to SL.
CO N FLI C T S O F I NTE R E S T
No competing interest declared.
AUTH O R CO NTR I B UTI O N
SL searched literature, drafted the manuscript, and critically revised the manuscript.
O RCI D
Sumei Liu http://orcid.org/0000-0002-8769-429X
